Navigation Links
Breast milk may provide a personalized screen of breast cancer risk
Date:4/4/2011

ORLANDO, Fla. Breast cancer risk can be assessed by examining the epithelial cells found in breast milk, according to preliminary study results presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

This screening method has the potential to provide a personalized assessment of breast cancer risk, said lead researcher Kathleen F. Arcaro, Ph.D., associate professor of veterinary and animal sciences at the University of Massachusetts Amherst. Given that roughly 80 percent of women give birth, this screen would also cover a large percentage of the female population.

Arcaro and colleagues collected breast milk samples from about 250 women who were scheduled for or who had a breast biopsy. The women submitted fresh samples, which were processed within 24 hours of expression; they provided samples from both breasts.

The researchers recruited about 90 percent of their study population from the Love/Avon Army of Women, which registers women who are willing to participate in breast cancer research. The American Association for Cancer Research is the scientific partner in this effort.

Once researchers received the samples, they isolated the epithelial cells (the potentially cancerous cells) in the breast milk. Then they isolated the DNA to look for epigenetic signals (attachment of methyl groups to DNA), which are the signals that tell the body those genes that should be expressed. These signals were then compared with breast cancer risk assessed using the biopsy results.

Arcaro and colleagues analyzed three genes: RASSF1, GSTP1 and SFRP1. "More than 35 genes have been shown to be methylated in breast cancer," she said.

Of the 104 women with a non-proliferative (low-risk) lesion, results showed no difference in the average epithelial DNA methylation of their biopsied breast vs. non-biopsied breast for RASSF1 and GSTP1. For SFRP1, however, the average methylation was higher in the biopsied breast. Importantly, among the women whose biopsies revealed cancer, there was a significant increase in average RASSF1 methylation in the biopsied breast vs. non-biopsied breast. Although the sample size in this study is small, "it's sufficient to tell us that we can use the cells in breast milk to assess breast cancer risk," Arcaro said, and additional studies are needed to expand the number of genes. Long-term studies are currently underway with about 80 percent of the original participants enrolled in follow-up.

Arcaro hopes that someday every woman who delivers a baby in a hospital will be screened for breast cancer via breast milk. "We'll take a little sample of colostrum, and we'll tell her how her breasts are doing," she said. "It's totally noninvasive, potentially inexpensive and really accurate."


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... FLINT, Mich. , Oct. 2, 2017 ... acquired 8th Day Software and Consulting, LLC , ... 8th Day Software, based in Tennessee ... Management LLC. 8th Day expands EnvoyHealth,s service offerings for ... product development. "In ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology: